FiercePharma12d
Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
Medscape11d
Cystic Fibrosis Transmembrane Conductance Regulator–Modifying Medications
combined groups: −5.4 mV (p < 0.001) CF = cystic fibrosis; FEV 1 = forced expiratory volume in 1 second. The classes of cystic fibrosis transmembrane conductance regulator (CFTR) mutations.
GlobalData on MSN12d
Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings
Vertex has won two cystic fibrosis approvals from the FDA, but the agency included high-level safety warnings.
Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek
Alyftrek is Vertex's fifth CFTR modulator to secure FDA approval. It is also under regulatory review in the European Union, the United Kingdom, Canada, Switzerland, Australia and New Zealand. Write to ...
MarketWatch15d
Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
The medicine, called trikafta, can treat cystic fibrosis patients who have at least one F508del mutation in the transmembrane conductance regulator gene or a mutation that is responsive to trikafta ...
Medical Xpress1mon
Cystic Fibrosis
CF is caused by a mutation in the gene for the protein cystic fibrosis transmembrane conductance regulator (CFTR). This gene is required to regulate the components of sweat, digestive juices ...
Yahoo Finance16d
Vertex Announces US FDA Approval of ALYFTREKâ„¢, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
- In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV 1 and further decreased sweat chloride compared to TRIKAFTA ® - BOSTON, December 20, 2024--(BUSINESS WIRE)--Vertex ...
Vertex's Cystic Fibrosis Drug Alyftrek Gets FDA Approval
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) Friday announced that the U.S. Food and Drug Administration (FDA) has approved Alyftrek for treatment of cystic fibrosis.
Business Insider15d
Vertex' Trikafta Gets Expanded FDA Approval For Cystic Fibrosis Treatment
ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to Trikafta based on clinical and/or ...
Joplin Globe15d
Vertex Announces US FDA Approval of ALYFTREKâ„¢, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
Vertex Announces US FDA Approval of ALYFTREKâ„¢, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis ...
Morningstar15d
Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek
It is the first once-daily treatment for cystic fibrosis transmembrane conductance regulator (CFTR) modulator, Vertex said. Alyftrek is Vertex's fifth CFTR modulator to secure FDA approval.
Morningstar15d
Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment
The medicine, called trikafta, can treat cystic fibrosis patients who have at least one F508del mutation in the transmembrane conductance regulator gene or a mutation that is responsive to ...